(DBVT) DBV Technologies S.A. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DBVT) DBV Technologies S.A. Complete Analysis Pack
DBV Technologies: Business Model Canvas Snapshot
Explore DBV Technologies S.A.’s Business Model Canvas to see how it creates value, targets key customers, and positions itself in a complex biotech market. This concise, company-specific breakdown helps you understand the core drivers behind its strategy and growth potential. Want the full picture? Purchase the complete Canvas for deeper insights.
Partnerships
Nestlé Health Science
DBV Technologies’ named partner on MAG1C is Nestlé Health Science. The collaboration targets a user-friendly atopy patch test for non-IgE mediated cow's milk protein allergy, a condition affecting about 2% to 5% of infants, and broadens DBV from epicutaneous immunotherapy into diagnostics.
Clinical trial investigators
DBV Technologies S.A. relies on clinical trial investigators to enroll patients, run protocols, and keep data clean across Viaskin Peanut, Viaskin Milk, and Viaskin Egg studies. They are critical to Phase III, Phase I/II, and pre-clinical readouts, so weak site execution can delay results and raise R&D costs.
Trial sites and hospitals
DBV Technologies S.A. relies on specialty trial sites and hospitals to recruit allergy patients and run immunotherapy studies across 3 groups: pediatric, adolescent, and adult. These sites also handle safety reporting, monitoring, and follow-up visits, which are critical in long allergy trials that can run for months or years.
Regulatory authorities
DBV Technologies S.A. depends on FDA, EMA, and other regulators because approval rules shape its trial design, endpoints, and filing path. For Viaskin Peanut, the FDA’s 2024 Complete Response Letter showed how regulatory feedback can delay the move from clinical stage to commercialization.
- Trial design follows regulator input.
- Endpoints must match approval rules.
- Filing strategy drives launch timing.
Manufacturing and development vendors
DBV Technologies S.A. depends on manufacturing and development vendors to formulate, test, and scale its patch platform, because clinical-stage biopharma usually outsources these steps. For a patch-based product, steady production and tight quality control are critical for trial supply and launch readiness, especially before any commercial-scale run.
- Supports formulation and scale-up.
- Helps keep trial supply consistent.
- Improves quality control before launch.
DBV’s Key Partners Could Shape Its Next Launch
DBV Technologies S.A. key partners are Nestlé Health Science for MAG1C, plus trial sites, investigators, regulators, and manufacturing vendors. These partners support development across Viaskin Peanut, Milk, and Egg, and matter because one FDA CRL in 2024 can shift launch timing. Nestlé targets a patch test for a condition affecting 2% to 5% of infants.
| Partner | Role | Why it matters |
|---|---|---|
| Nestlé Health Science | MAG1C co-development | Expands DBV into diagnostics |
| Sites and investigators | Trial execution | Drive enrollment and data quality |
| Regulators and vendors | Approval and supply | Shape timing and launch readiness |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas showing how DBV Technologies creates, delivers, and captures value across all 9 blocks.
Customizable Excel Spreadsheet
Quickly shows how DBV Technologies S.A. addresses key pain points with a clear, editable business model snapshot.
Reference Sources
Provides a clear source trail for DBV Technologies S.A., boosting credibility and helping decision-makers verify key claims fast.
Activities
Phase III development of Viaskin Peanut
Phase III development of Viaskin Peanut is DBV Technologies S.A.'s most advanced program, with 3 completed Phase III trials in peanut allergy across children aged 4 to 11, adolescents, and adults. This key activity is focused on proving efficacy and safety for registration, which is the last major step before potential market approval.
Phase I/II development of Viaskin Milk
DBV Technologies is advancing Viaskin Milk in Phase I/II for IgE-mediated cow’s milk protein allergy, a condition affecting about 2% to 3% of infants. Early testing is meant to set dose, check tolerability, and measure immune response, while also extending DBV’s epicutaneous patch platform beyond peanut allergy.
Pre-clinical development of Viaskin Egg
DBV Technologies S.A. keeps Viaskin Egg in pre-clinical development, where the work centers on candidate design, lab testing, and translational studies before any human trial. This stage is a low-cost pipeline bet compared with clinical programs, and DBV Technologies S.A. has not yet disclosed any 2025 clinical efficacy data for the egg allergy program.
MAG1C diagnostic test development
DBV Technologies S.A. and Nestlé Health Science are developing MAG1C to diagnose non-IgE mediated cow’s milk protein allergy in infants and toddlers, a condition that affects about 2% to 5% of children under 2. This activity links device development with diagnostic validation, so DBV Technologies S.A. can build a second revenue line beyond therapy if the test reaches clinical use.
- Targets infants and toddlers
- Combines device and diagnostics
- Supports a second business line
Discovery research in immune diseases and vaccines
DBV Technologies S.A. uses discovery research in immune diseases and vaccines to keep several long-shot options alive while core programs mature. Its pipeline spans a pertussis booster, an RSV vaccine, Crohn’s disease, celiac disease, and type I diabetes, so the patch platform has a wider long-term innovation base.
- Broadens future pipeline options
- Supports vaccine and autoimmune research
- Keeps early-stage bets active
DBV Technologies Advances Viaskin Pipeline Across Peanut, Milk, and Egg
DBV Technologies S.A. runs a patch-based pipeline led by Viaskin Peanut, with 3 completed Phase III trials in children 4 to 11, adolescents, and adults, plus Viaskin Milk in Phase I/II and Viaskin Egg in pre-clinical work. It also co-develops MAG1C with Nestlé Health Science for non-IgE cow’s milk allergy, while early immune and vaccine research keeps longer-term options alive.
| Key activity | Stage | Data point |
|---|---|---|
| Viaskin Peanut | Phase III | 3 trials completed |
| Viaskin Milk | Phase I/II | IgE milk allergy |
Preview Before You Purchase
Business Model Canvas
The DBV Technologies S.A. Business Model Canvas previewed here is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see is a live snapshot of the final file. Once you buy, you’ll download the same complete, ready-to-use document with the same layout and content.
Resources
Viaskin epicutaneous platform
Viaskin is DBV Technologies S.A.’s core proprietary epicutaneous platform, designed to deliver allergens through the skin and support its main allergy programs. In 2025, that single technology still sat at the center of DBV’s R&D model, with the company remaining a clinical-stage business and not generating product sales.
Clinical-stage pipeline
DBV Technologies S.A.'s clinical-stage pipeline spans Viaskin Peanut, Viaskin Milk, Viaskin Egg, MAG1C, and other research programs, so the Company has at least 5 shots on goal. A multi-asset pipeline cuts dependence on one readout and opens several value-creation paths as each program moves through development.
Clinical data and trial results
DBV Technologies S.A.’s key resource is its clinical data package, led by Phase III EPITOPE results from 462 toddlers with peanut allergy and earlier Phase I/II VIASKIN studies. These data anchor FDA and EMA talks, support investor and partner interest, and guide the next trial design for dose, age, and endpoint choices.
Scientific and regulatory expertise
DBV Technologies S.A. relies on deep scientific and regulatory expertise to build allergy immunotherapy, diagnostics, and vaccine programs. As a clinical-stage Company, it must design trials, meet FDA and EMA rules, and file clean submissions, because one weak protocol can delay years of work.
- Trial design and safety review
- Regulatory filing strategy
- Allergy and vaccine know-how
Partnership network with Nestlé Health Science
DBV Technologies S.A.’s partnership network with Nestlé Health Science is a strategic key resource because the MAG1C collaboration adds outside expertise and market access, which matters in diagnostics and future commercialization. It also helps validate DBV Technologies S.A.’s platform beyond therapeutics, while Nestlé Health Science’s global nutrition and medical platform gives the alliance scale that DBV Technologies S.A. does not have alone.
- MAG1C adds external know-how
- Boosts market access and reach
- Supports non-therapeutic validation
- Strength matters for commercialization
DBV’s Viaskin platform and EPITOPE data keep the pipeline moving
DBV Technologies S.A.’s key resources are its Viaskin epicutaneous platform, its clinical data, and its regulatory know-how. In 2025, EPITOPE still anchored the story: Phase III data covered 462 toddlers with peanut allergy, while the pipeline kept at least 5 programs in play.
| Resource | 2025-2026 data |
|---|---|
| EPITOPE | 462 toddlers |
| Pipeline | 5+ programs |
Value Propositions
Epicutaneous allergy treatment
DBV Technologies S.A. uses an epicutaneous patch to deliver tiny allergen doses through the skin, avoiding injections and oral dosing, which can make use easier for patients and caregivers. Its lead food-allergy program, Viaskin Peanut, has been studied in children as young as 4 with a 250 µg dose for desensitization.
Peanut allergy focus
Viaskin Peanut targets peanut allergy, which affects about 2% of children in the United States and can persist into adulthood, making it one of the highest-need food allergy markets. DBV Technologies S.A. has completed Phase III testing for Viaskin Peanut, giving it a near-term lead asset in a market where even small efficacy gains can reach a large patient base.
Broader food allergy pipeline
DBV Technologies S.A. is not just a peanut-allergy story: its Viaskin platform also targets cow’s milk and hen’s egg allergy through Viaskin Milk and Viaskin Egg. That broader pipeline gives the Company three allergy indications to build on, which can support longer-term growth beyond a single market.
Non-invasive diagnostic option
MAG1C gives DBV Technologies S.A. a non-invasive way to help diagnose non-IgE mediated cow’s milk protein allergy in infants and toddlers, a group where diagnosis is often slow and unclear. Cow’s milk protein allergy affects about 2% to 3% of infants, so a simple patch test can cut clinic time, ease parent stress, and improve workflow.
- Non-invasive patch test
- Built for hard-to-diagnose infants
- Can simplify clinic flow
Platform extensibility
DBV’s Viaskin platform is being applied beyond allergy into vaccines and other immune-mediated diseases, so one core technology can support more than one market. That optionality matters: if even one new program moves forward, it can lift the platform’s strategic value beyond the allergy franchise.
- One core platform, multiple disease areas
- Reduces dependence on allergy alone
- Successful early programs can re-rate value
DBV’s Patch Platform Targets Peanut Allergy Relief for Kids
DBV Technologies S.A. offers a non-invasive epicutaneous patch platform that can improve use, comfort, and caregiver ease versus injections or oral dosing. Its lead value driver is Viaskin Peanut, studied in children aged 4-11 with a 250 µg dose, aimed at a peanut allergy market affecting about 2% of U.S. children.
| Asset | Value prop | Key fact |
|---|---|---|
| Viaskin Peanut | Patch desensitization | Phase III; 250 µg |
| MAG1C | Patch diagnosis | For milk allergy |
Customer Relationships
Clinical specialist engagement
DBV Technologies S.A. relies on allergists, pediatricians, and trial centers to build trust in a prescription and diagnostic setting. Its lead VIASKIN Peanut program has been tested in a 462-patient Phase 3 study, so specialist engagement depends on clear clinical data, hands-on training, and fast medical information.
Partner collaboration model
DBV Technologies S.A. works with Nestlé Health Science on MAG1C through a milestone-based model that ties technical work to shared development steps, which helps limit development risk. The partnership structure matters because each stage is coordinated across both teams, and DBV Technologies S.A. reported €13.2 million in collaboration and other income in the first half of 2024, showing this kind of partner support is financially relevant.
Medical education support
Medical education support matters because allergy patches need clear guidance on use, safety, and patient selection. DBV Technologies S.A. still had no product sales in 2025, so helping clinicians understand the epicutaneous platform is a key step to drive future adoption if the products reach the market.
Patient and caregiver communication
Food allergy care can last years, and about 8% of U.S. children and 11% of adults live with food allergies, so DBV Technologies S.A. must keep parents, caregivers, and patients clear on expected benefits, daily use, and safety. Strong, ongoing communication helps people stay in studies and stick with treatment.
- Explain safety in plain words
- Set clear treatment expectations
- Support long-term adherence
- Reduce study dropouts
Regulatory and investigator feedback loops
DBV Technologies S.A. keeps investigators and regulators in the loop because, in clinical development, their feedback can drive protocol amendments, endpoint choices, and later labeling plans. For a company still pre-launch, these relationships can matter as much as trial data itself, since they shape what the FDA and other agencies will accept.
- Feedback can change trial design fast
- Endpoints must fit regulatory review
- Labeling strategy starts before launch
DBV’s Trust-First Strategy Powers VIASKIN’s Next Growth Phase
DBV Technologies S.A. builds customer relationships around specialist trust, patient education, and regulator feedback, because its VIASKIN platform needs clear clinical proof and day-to-day guidance. In 2025, it still had no product sales, so allergists, pediatricians, trial sites, and families are the core link to future adoption.
| Key data | Value |
|---|---|
| VIASKIN Phase 3 | 462 patients |
| H1 2024 collaboration income | €13.2 million |
| U.S. food allergies | 8% children, 11% adults |
| 2025 product sales | €0 |
Channels
Clinical trial sites
Clinical trial sites are DBV Technologies S.A.'s main channel to reach study participants, since its pipeline is still clinical-stage and needs site-led enrollment, dosing, monitoring, and data capture. In 2025, the company’s core work remained centered on site-run studies, making each active site a direct driver of trial speed and cost control.
Specialist healthcare providers
Allergy specialists and pediatric clinicians are the key gatekeepers for DBV Technologies S.A. if Viaskin Peanut wins approval. DBV’s science message should speak to their needs: clear efficacy, safety, and diagnosis data, especially for the 462 children enrolled in the EPITOPE phase 3 trial.
Diagnostic collaboration channels
MAG1C can reach users through clinical diagnostics partnerships, so DBV Technologies S.A. can plug product development into lab and practice workflows faster. The Nestlé Health Science collaboration gives it one clear partner-led channel for clinical use and adoption.
That model matters because diagnostics partners can help move MAG1C from development into routine testing with fewer handoffs between labs and clinics. For DBV Technologies S.A., the channel is less about direct sales and more about embedded clinical access.
Regulatory submission pathways
DBV Technologies S.A.’s route to market runs through the FDA and EMA, where review timelines are set by process: the FDA’s standard clock is about 10 months, while the EMA’s active-review cycle is 210 days. Strong submission quality matters because every major deficiency can add months and delay revenue.
- FDA: ~10-month standard review
- EMA: 210-day active review
- Better files mean faster approval
Investor and corporate communications
DBV Technologies S.A. relies on investor and corporate communications to keep capital markets aligned on trial readouts, milestones, and partnership news. As a clinical-stage biotech with no marketed products, these channels help support financing and signal credibility to investors.
- Trial updates drive valuation.
- Milestones support fundraises.
- Partnerships build trust.
DBV’s 2025 Growth Hinges on Clinical Trial Execution
DBV Technologies S.A. uses clinical trial sites, allergy specialists, and diagnostics partners as its main channels, because its 2025 business stayed clinical-stage and revenue still depends on study execution, not product sales. The EPITOPE phase 3 trial enrolled 462 children, so site quality and clinician access directly affect speed and data quality.
| Channel | Key data |
|---|---|
| Clinical sites | 2025 trial execution |
| Allergy clinicians | 462 EPITOPE children |
| Regulators | FDA ~10 months; EMA 210 days |
Customer Segments
Children with peanut allergy
Children aged 4 to 11 with peanut allergy are DBV Technologies S.A.'s core target for Viaskin Peanut, which has completed Phase III trials in this age group. Pediatric food allergy remains a major unmet need, with peanut allergy affecting about 2% of children in many Western markets.
Adolescents and adults with peanut allergy
DBV Technologies S.A.'s peanut program includes adolescents and adults, not just children, which can expand the addressable base beyond the 4-11 age group used in earlier studies. That wider age range can also fit different regulatory and commercial paths, since peanut allergy often persists into later life.
Patients with cow’s milk allergy
Patients with cow’s milk allergy are a large, burdened segment: IgE-mediated cow’s milk allergy affects about 2% to 3% of infants and young children, and many still live with strict avoidance, nutrition limits, and accidental-exposure risk. Viaskin Milk targets this group and gives DBV Technologies S.A. a second therapeutic market beyond peanut allergy.
Infants and toddlers needing diagnosis
MAG1C targets infants and toddlers with suspected non-IgE mediated cow’s milk protein allergy, a condition seen in about 2% to 3% of infants. This segment needs practical, low-burden diagnostic tools, because faster confirmation can cut feeding changes, clinic visits, and family stress.
By shortening the path to diagnosis, DBV Technologies S.A. can help clinicians act sooner and reduce uncertainty at a stage when symptoms are often vague.
- Targets very young children
- Helps confirm non-IgE CMPA
- Reduces diagnostic delay
- Lowers family uncertainty
Healthcare providers and specialty centers
Doctors, allergy clinics, hospitals, and pediatric centers are the core professional buyers for DBV Technologies S.A. because they administer, recommend, and interpret the products that support diagnosis and care. Food allergy affects about 1 in 13 children in the U.S., so clinical adoption matters: without specialist buy-in, commercialization slows fast.
- Key users: doctors and allergy specialists
- Core sites: hospitals and pediatric centers
- Adoption drives diagnosis and use
- High need: about 1 in 13 children
DBV Targets Kids’ Food Allergies With Peanut Therapy and Faster Milk Allergy Diagnosis
DBV Technologies S.A. mainly serves children with peanut allergy, plus adolescents and adults if Viaskin Peanut gains broader labeling. It also targets infants with cow’s milk allergy and clinicians using MAG1C for faster non-IgE CMPA diagnosis; food allergy affects about 1 in 13 U.S. children.
| Segment | Need |
|---|---|
| Children 4 to 11 | Peanut allergy therapy |
| Infants and toddlers | CMPA diagnosis |
| Clinics and hospitals | Testing and treatment use |
Cost Structure
Clinical trial expenses
Clinical trial expenses are DBV Technologies S.A.'s biggest cost driver: Phase III work can run into tens of millions of euros, with cash going to patient recruitment, site management, data capture, and safety monitoring. For a clinical-stage biotech, these R&D outlays usually dominate the cost base and can stay high through 2025/2026 as studies scale.
Research and development spend
DBV Technologies S.A. puts research and development at the center of its cost base, funding discovery, pre-clinical work, and clinical development across allergy, vaccine, and immune-disease programs. In biotech, this is the main long-term cash use, and for DBV it supports platform growth rather than near-term sales.
Manufacturing and quality costs
DBV Technologies S.A.’s patch-based programs need repeatable production, release testing, and stability studies, so manufacturing and quality costs step up as development moves into scale-up and launch readiness. In 2025/2026, the main cost drivers are GMP batches, validation runs, and quality systems built for regulatory filing and commercial supply.
Regulatory and compliance costs
Regulatory and compliance costs are a core overhead for DBV Technologies S.A., because every submission, audit, document set, and pharmacovigilance review must stay active through development. For clinical and diagnostic products, the same quality and safety systems must support trials, labeling, and post-market controls, so this spend is recurring, not one-off.
- Submissions and audits drive fixed overhead.
- Pharmacovigilance runs throughout development.
- Clinical and diagnostic products need strict controls.
These costs rise with each program milestone and regulator request.
General and administrative costs
DBV Technologies S.A. must keep general and administrative costs tight because they cover staff, corporate overhead, legal work, and public-company reporting for a listed biotech in Montrouge, France. These costs also support financing work, so any rise in headcount or filing burden can quickly pressure cash use and dilute runway.
- Staffing and corporate overhead
- Legal and listing compliance
- Supports financing activity
DBV’s 2025/2026 Costs Are Still Driven by R&D and Clinical Work
DBV Technologies S.A.’s cost base is still dominated by R&D, with clinical trials, GMP manufacturing, regulatory work, and quality systems taking most of the cash in 2025/2026. General and administrative costs stay smaller but matter for a listed biotech because they cover staff, legal, reporting, and financing work.
| Cost item | 2025/2026 driver |
|---|---|
| R&D | Clinical trials, pre-clinical work |
| Manufacturing | GMP batches, validation, testing |
| Regulatory | Filings, audits, pharmacovigilance |
| G&A | Staff, legal, listing costs |
Revenue Streams
Potential product sales
If Viaskin Peanut gets approved, DBV Technologies S.A. could earn direct product sales, and that would be its main long-term revenue engine. In 2025, the company still had no commercial product revenue, so sales would hinge on approval, pricing, and real-world adoption.
Diagnostic product sales
DBV Technologies S.A. had no diagnostic product sales revenue in its latest reported 2025/2026 filings, so MAG1C could create a new standalone line in allergy diagnostics. A user-friendly patch test sold through clinics and labs would diversify income beyond therapeutics, which is important for a company still funded mainly by cash and R&D spending.
Licensing and partnership income
DBV Technologies S.A. can turn its platform into licensing and partnership cash through collaboration deals that usually pay an upfront fee, then milestones and royalties later; Nestlé Health Science is the clearest live example, alongside DBV’s 2023 revenue of €11.9 million.
This model matters because one signed partner can fund development without heavy dilution, while success fees rise if the platform reaches regulatory and sales targets.
Milestone payments
Milestone payments are a key biotech revenue stream for DBV Technologies S.A. because they can arrive when partners hit clinical, regulatory, or launch steps, helping fund work before product sales start. In DBV’s latest public reporting, the company still depends on external financing and partnership-linked cash flow rather than product revenue, so each milestone can matter a lot.
- Linked to clinical progress
- Triggered by FDA or EMA filings
- Can fund development before launch
Future royalties and commercial agreements
Future royalties and commercial agreements could become DBV Technologies S.A.'s main post-approval revenue stream if partnered products reach the market. In biotech, royalties often scale with product sales, so income can grow faster than internal manufacturing revenue; for DBV Technologies S.A., this model would matter most once commercialization starts.
- Scales with partner sales, not plant output
- Typical for post-approval biotech deals
DBV’s Revenue Still Runs on Partner Cash, Not Product Sales
DBV Technologies S.A.'s revenue streams still center on partnership cash, not sales: 2025 product revenue was nil, so upfront fees, milestones, and royalties remain the core levers. If Viaskin Peanut or MAG1C reach approval, direct sales could add a new line, but cash generation still depends on partner-funded progress.
| Stream | Latest data |
|---|---|
| Product sales | €0 in 2025 |
| Total revenue | €11.9m in 2023 |
| Partner cash | Upfronts, milestones, royalties |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.